Clinical Trial: A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma.

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391657) titled 'A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma.' on Jan. 30.

Brief Summary: This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in participants with RRMM.

Study Start Date: Feb. 09

Study Type: INTERVENTIONAL

Condition: Relapsed Refractory Multiple Myeloma

I...